Company Description
NEXGEL, Inc. manufactures and sells high water content, electron beam cross-linked, and aqueous polymer hydrogels and gels for wound care, medical diagnostics, transdermal drug delivery, and cosmetics in the United States.
It operates through two segments, Nexgel and CG labs. The company offers over-the-counter remedy solutions, such as blister and pain applications under the MedaGel brand; and beauty and cosmetic solutions, such as wrinkle and skin cream applications under the LumaGel Beauty brand name.
It is also developing NEXDrape, an incise surgical drape designed for patients with impaired skin; and NEXDerm, an adhesive tape designed to secure central lines and intravenous tubes and devices to patients before, during, and after medical treatment.
In addition, the company engages in the converting and packaging business. The company was formerly known as AquaMed Technologies, Inc. and changed its name to NEXGEL, Inc. in November 2019.
The company was incorporated in 2009 and is based in Langhorne, Pennsylvania.
| Country | United States |
| Founded | 1997 |
| IPO Date | Dec 22, 2021 |
| Industry | Medical Instruments & Supplies |
| Sector | Healthcare |
| Employees | 19 |
| CEO | Adam R. Levy |
Contact Details
Address: 2150 Cabot Blvd West, Suite B Langhorne, Pennsylvania 19047 United States | |
| Phone | 215 702-8550 |
| Website | nexgel.com |
Stock Details
| Ticker Symbol | NXGL |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $5.50 |
| CIK Code | 0001468929 |
| CUSIP Number | 65344E107 |
| ISIN Number | US65344E1073 |
| Employer ID | 26-4042544 |
| SIC Code | 3841 |
Key Executives
| Name | Position |
|---|---|
| Adam R. Levy | Chief Executive Officer, President and Director |
| Adam E. Drapczuk III | Chief Financial Officer |
| Gregory Robb | Vice President of Operations |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| May 13, 2024 | 8-K | Current Report |
| May 13, 2024 | 10-Q | Quarterly Report |
| May 3, 2024 | DEFR14A | Filing |
| Apr 29, 2024 | DEF 14A | Other definitive proxy statements |
| Apr 10, 2024 | 10-K | Annual Report |
| Apr 2, 2024 | NT 10-K | Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 |
| Apr 1, 2024 | 8-K | Current Report |
| Feb 21, 2024 | 424B5 | Filing |
| Feb 21, 2024 | 8-K | Current Report |
| Jan 31, 2024 | 8-K | Current Report |